A Randomized, Open-label, Fasting, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers
Latest Information Update: 26 Mar 2025
At a glance
- Drugs BR 3409 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 26 Mar 2025 New trial record